Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more
Ascendis Pharma AS (ASND) - Total Liabilities
Latest total liabilities as of December 2025: $1.46 Billion USD
Based on the latest financial reports, Ascendis Pharma AS (ASND) has total liabilities worth $1.46 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ascendis Pharma AS - Total Liabilities Trend (2011–2025)
This chart illustrates how Ascendis Pharma AS's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ascendis Pharma AS Competitors by Total Liabilities
The table below lists competitors of Ascendis Pharma AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wal-Mart de México S.A.B. de C.V
MX:WALMEX
|
Mexico | MX$263.41 Billion |
|
Omega Healthcare Investors Inc
NYSE:OHI
|
USA | $4.61 Billion |
|
Api Group Corp
NYSE:APG
|
USA | $5.45 Billion |
|
TransUnion
NYSE:TRU
|
USA | $6.57 Billion |
|
Carlisle Companies Incorporated
NYSE:CSL
|
USA | $4.47 Billion |
|
NEXT plc
PINK:NXGPF
|
USA | $3.47 Billion |
|
Repsol S.A
OTCQX:REPYF
|
USA | $32.71 Billion |
|
Samsung Life
KO:032830
|
Korea | ₩285.85 Trillion |
Liability Composition Analysis (2011–2025)
This chart breaks down Ascendis Pharma AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -9.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ascendis Pharma AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ascendis Pharma AS (2011–2025)
The table below shows the annual total liabilities of Ascendis Pharma AS from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.46 Billion | +13.97% |
| 2024-12-31 | $1.29 Billion | +32.32% |
| 2023-12-31 | $971.28 Million | +17.53% |
| 2022-12-31 | $826.39 Million | +310.56% |
| 2021-12-31 | $201.29 Million | +42.67% |
| 2020-12-31 | $141.08 Million | +77.20% |
| 2019-12-31 | $79.62 Million | +104.58% |
| 2018-12-31 | $38.92 Million | +63.74% |
| 2017-12-31 | $23.77 Million | +76.61% |
| 2016-12-31 | $13.46 Million | +17.59% |
| 2015-12-31 | $11.45 Million | -11.01% |
| 2014-12-31 | $12.86 Million | -36.95% |
| 2013-12-31 | $20.40 Million | -14.47% |
| 2012-12-31 | $23.85 Million | +5.60% |
| 2011-12-31 | $22.59 Million | -- |